{"id":"W2954887335","doi":"10.1212/nxi.0000000000000590","title":"Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP","year":2019,"lang":"en","type":"article","venue":"Neurology Neuroimmunology & Neuroinflammation","topic":"Peripheral Neuropathies and Disorders","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; University Health Network","funders":"Japan Society for the Promotion of Science; Sanofi Genzyme; Novartis Pharma; Grifols; Ono Pharmaceutical; Mitsubishi Tanabe Pharma Corporation; Teijin Pharma; Bayer Yakuhin; Celgene; Ministry of Education, Culture, Sports, Science and Technology; Pfizer Japan; Shionogi; Argenx; Ministry of Health, Labour and Welfare; Eisai; Japan Blood Products Organization; Boehringer Ingelheim Japan; Kissei; Neurocrine Biosciences; Pfizer; Biogen; Alnylam Pharmaceuticals; Alexion Pharmaceuticals; Heinrich-Heine-Universität Düsseldorf; Bristol-Myers Squibb; GBS/CIDP Foundation International; Teva Pharmaceutical Industries; Myasthenia Gravis Foundation of America; Bayer HealthCare; Kowa Company; Sanofi; CSL Behring","keywords":"Medicine; Chronic inflammatory demyelinating polyneuropathy; Adverse effect; Internal medicine; Polyradiculoneuropathy; Gastroenterology; Surgery; Antibody; Pediatrics; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001925503,0.0003710045,0.0006244287,0.0001482917,0.0001500261,0.0003272831,0.0003706965,0.0005160821,0.000948062],"category_scores_gemma":[0.001847963,0.0001279776,0.0003573629,0.0001486236,0.000430275,0.0004784416,0.0001882366,0.0007477265,0.0002289786],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002344454,"about_ca_system_score_gemma":0.0002950297,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001459025,"about_ca_topic_score_gemma":0.0001610513,"domain_scores_codex":[0.999436,0.0002762158,0.00004524098,0.00006343332,0.0001159047,0.00006316927],"domain_scores_gemma":[0.9984268,0.0004590394,0.0006785754,0.0001253383,0.0000982506,0.0002120823],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.3651654,0.01729727,0.1357742,0.001102904,0.001087562,0.0009798456,0.000321277,0.002714577,0.1183442,0.000151873,0.001046742,0.3560142],"study_design_scores_gemma":[0.03133637,0.6909948,0.2480955,0.0001228204,0.000739727,0.002292033,0.0001062167,0.002290762,0.02140228,0.0001200964,0.002462133,0.00003725937],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9969072,0.002381838,0.0001947199,0.00003773662,0.00001004202,0.00004126813,0.00009112546,0.00001317717,0.0003230616],"genre_scores_gemma":[0.9988753,0.0004512163,0.0001654328,0.00005967657,0.00004213026,0.00004147325,0.0001796484,0.000002639404,0.0001823779],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001925503,"threshold_uncertainty_score":0.01018316,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.00639744829432481,"score_gpt":0.2298394140922261,"score_spread":0.2234419657979012,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}